The purpose of this study is to assess the safety and efficacy of Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim in neoadjuvant treatment of potentially resectable Biliary Tract Neoplasms.
Male or female
Age ≥ 18 years，≤ 75 years
Patients with untreated resectable locally advanced biliary tract cancer (BTC) who are difficult to directly resecte surgically
Ability to provide written informed consent prior to participation in any study-related procedure
Diagnosis of mixed ampullary, hepatocellular, and cholangiocarcinoma
Known history of a serious allergy to any monoclonal antibody
Any active malignancy prior to the start of treatment
Active or history of autoimmune disease